Precision Psychiatry Market Demonstrates Long-Term Growth Potential At 14.4% CAGR

The field of precision psychiatry is rapidly evolving, driven by advances in technology and a growing focus on personalized mental healthcare. This market is set to witness substantial growth as new innovations and increased investments come into play. Below, we explore the market's projected value, leading companies, emerging trends, and key segments shaping its future.

Forecasted Value and Growth Potential in the Precision Psychiatry Market
The precision psychiatry market is projected to expand significantly, reaching a value of $9.81 billion by 2030. This represents a robust compound annual growth rate (CAGR) of 14.4%. Several factors are fueling this rise, including heightened investment in precision medicine platforms, greater adoption of AI-powered diagnostic tools, growth in digital mental health solutions, increasing demand for personalized psychiatric care, and a stronger emphasis on preventive mental health approaches. Expected trends over the coming years include wider use of biomarker-guided treatment pathways, digital phenotyping tools, integration of genetic and neuroimaging data, AI-enhanced clinical decision support, and more personalized mental health monitoring methods.

The precision psychiatry market size has grown rapidly in recent years. It will grow from $4.99 billion in 2025 to $5.72 billion in 2026 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to increasing prevalence of mental health disorders, growing limitations of trial-and-error prescribing, expansion of psychiatric research initiatives, rising availability of neuroimaging technologies, early adoption of pharmacogenomics in psychiatry.

Download a free sample of the precision psychiatry market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30359&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Market Players Leading the Precision Psychiatry Industry
The precision psychiatry sector is dominated by several prominent companies, such as Johnson & Johnson, F. Hoffmann-La Roche Ltd, Pfizer Inc., AbbVie Inc., AstraZeneca plc, Novartis AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Otsuka Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Illumina Inc., ARUP Laboratories Inc., Sumitomo Dainippon Pharma Company Limited, QIAGEN N.V., Neurocrine Biosciences Inc., Tempus Labs Inc., Myriad Genetics Inc., MedGenome Labs Ltd., and Genomind Inc.

A notable activity in early 2025 was Johnson & Johnson's acquisition of Intra-Cellular Therapies Inc. for about $14.6 billion. This strategic move aims to enhance Johnson & Johnson's portfolio of innovative psychiatric drugs and leverage Intra-Cellular Therapies' specialized expertise in mechanism-based drug development for central nervous system disorders. Intra-Cellular Therapies is recognized for its targeted neuropsychiatric treatments that align closely with precision psychiatry principles.

View the full precision psychiatry market report:
https://www.thebusinessresearchcompany.com/report/global-precision-psychiatry-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Innovation Trends in Precision Psychiatry
The market's leading companies are actively pursuing the development of novel therapies, including prescription digital therapeutics designed to deliver personalized, data-driven psychiatric care. These therapeutics involve clinician-prescribed software interventions that provide evidence-based behavioral therapy through mobile devices, supporting improved symptom management and treatment adherence. For instance, in August 2024, Otsuka Precision Health Inc., a subsidiary of Otsuka Holdings, partnered with Click Therapeutics Inc. to introduce Rejoyn. This product is the first prescription digital therapeutic cleared by the FDA for adjunctive treatment of major depressive disorder (MDD) symptoms. Rejoyn offers a six-week cognitive-emotional training program combining emotional faces memory tasks with cognitive behavioral therapy (CBT) modules, alongside features for digital prescribing, patient engagement, and remote monitoring. This launch marks a significant breakthrough in precision psychiatry, illustrating how digital therapeutics can complement traditional medications and promote personalized treatment. It also sets a precedent for broader use of software-based interventions that harness real-time patient data to optimize results and adherence.

Segment Analysis Highlighting the Precision Psychiatry Market's Growth Drivers
The precision psychiatry market can be segmented into several key categories:

1) Therapeutic Approaches: including pharmacotherapy, psychotherapy, neurostimulation, digital therapeutics, and combination therapies.
2) Technology Platforms: encompassing genetic testing, biomarker analysis, brain imaging techniques, wearable devices, and AI and machine learning-driven solutions.
3) Psychiatric Disorders: such as depression, anxiety disorders, bipolar disorder, schizophrenia, and post-traumatic stress disorder (PTSD).
4) Application Areas: covering diagnosis, treatment, and research.
5) End Users: including clinics, hospitals, research institutes, pharmaceutical companies, and home care settings.

Further detailed subsegments include:

- Pharmacotherapy categories like antidepressants, antipsychotics, mood stabilizers, anxiolytics, and stimulants.
- Psychotherapy modalities such as cognitive behavioral therapy, interpersonal therapy, psychodynamic therapy, dialectical behavior therapy, and mindfulness-based therapy.
- Neurostimulation techniques including transcranial magnetic stimulation, electroconvulsive therapy, vagus nerve stimulation, deep brain stimulation, and transcranial direct current stimulation.
- Digital therapeutics covering mobile app-based therapies, virtual reality therapy, web-based CBT programs, remote patient monitoring tools, and AI-guided interventions.
- Combination therapies involving various mixes of pharmacotherapy, psychotherapy, neurostimulation, and digital therapeutics, as well as multimodal precision treatment programs.

This comprehensive segmentation reflects the multifaceted nature of precision psychiatry and highlights the diverse avenues contributing to the market's rapid growth and innovation.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.